PEDIATRICS Vol. 71 No. 2 February 1983, pp. 187-191
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaplan, S. L.
Right arrow Articles by Feigin, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaplan, S. L.
Right arrow Articles by Feigin, R. D.

Moxalactam Treatment of Serious Infections Primarily Due to Haemophilus influenzae Type b in Children

Sheldon L. Kaplan MD1, Edward O. Mason Jr PhD1, Sally J. Kvernland RN1, Elaine M. Loiselle RN1, and Ralph D. Feigin MD1

1 From the Myers-Black Infectious Diseases Section, Department of Pediatrics, Baylor College of Medicine, and C. T. Parker Memorial Laboratory, Texas Children's Hospital, Houston

Thirty-eight children completed therapy with moxalactam for a variety of non-CNS infections. Haemophilus influenzae type b (seven ampicillin-resistant strains) was the etiologic agent for 32 children. Doses of moxalactam ranged from 113 to 200 mg/kg/d in three or four divided doses administered parenterally. All children with infections due to H influenzae type b had excellent responses to moxalactam therapy. Children treated for infections due to other agents also responded satisfactorily to moxalactam therapy. Moxalactam concentrations in joint and pleural fluids greatly exceeded the minimal bactericidal concentrations of moxalactam for H influenzae type b. Adverse reactions included neutropenia, eosinophilia, thrombocytosis, and transient elevation of transaminase levels. Moxalactam administered parenterally, at a dose of 113 to 150 mg/kg/d in three or four divided doses is effective therapy for serious infections in children due to H influenzae type b and selected other organisms.

Key Words: moxalactam • Haemophilus influenzae type b • neutropenia

Submitted on March 5, 1982
Accepted on May 6, 1982